tbuckley/cabot-search huggingface dataset:
2198P Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Authors: M. Makarem, B. Ricciuti, J.V. Alessi, F. Pecci, A. Di Federico, M. Gandhi, P.A. Jänne, M.M. Awad, J.K. Rotow
Journal: Annals of Oncology (2023)
1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Authors: R.F. Schlenk, M. Oleś, S. Bauer, T. Kindler, F. Klauschen, C.H. Brandts, D.T. Rieke, L. Illert, M. Börries, C. Heining, P. Horak, M. Bitzer, U. Dirksen, M. Sparber-Sauer, M-V. Teleanu, S. Kreutzfeldt, H. Glimm, D. Hübschmann, C.E. Heilig, S. Fröhling
Journal: Annals of Oncology (2023)
1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Authors: G. Evers, L.E. Reitnauer, D.C.C. Christoph, W.M. Brueckl, M. Wiesweg, F. Glanemann, M. Webendoerfer, C. Kropf, F. Acker, A-C. Hund, W. Schütte, P. Hoffknecht, A. Kerkhoff, M. Mohr, G. Lenz, N. Frost, T.R. Overbeck, M. Sebastian, A. Bleckmann
Journal: Annals of Oncology (2023)
2401P Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
Authors: R. Zhang, H. Tang, J. Zang, D. Jin, L. Qian, T. Zhang, F. Xie, Y. Zhang, X. Zhang, S. Jia, G. Zhuang, H. Chen
Journal: Annals of Oncology (2023)
1307P The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Authors: L. Robertson, P. Taniere, M. Smith, M. Lockwood, K. Charles, A. Iqbal, B. O'Sullivan, S. Diaz-Cano
Journal: Annals of Oncology (2023)
731P REWENEC: REal-World Evidence in NEC provides a reliable external control arm to avoid randomization for second-line clinical trials - A post hoc proof of concept analysis with the randomized phase II BEVANEC study
Authors: J. Hadoux, S. Ganame, A. Lievre, A. Durand, D. Tougeron, None M. perrier, J-Y. Scoazec, E. Baudin, L. Gerard, C. Lepage, O. Boussari, T. Walter
Journal: Annals of Oncology (2023)
2168P At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Authors: J. Marco Hernández, E. Güell, C. Zamora, P. Ayora, V.M. Albarran Artahona, G. Carrera, C. Gallego, I. Grafiá, J. Padrosa, M. Viladot, A. Tuca, L. Corominas, A. Prat, F. Fernández Avilés
Journal: Annals of Oncology (2023)
1309P Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Authors: L. Sellmer, A. Bogler, J. Kovacs, J. Walter, R. Kiefl, D. Kauffmann-Guerrero, T.A. Bolt, C. Schneider, A. Tufman
Journal: Annals of Oncology (2023)
1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Authors: P.N. Lara, C. Tangen, E. Heath, M. Stein, M. Meng, A. Alva, S.K. Pal, I. Puzanov, J. Clark, T.K. Choueiri, N. Agarwal, R. Uzzo, N.B. Haas, M. Plets, U.N. Vaishampayan, None B. shuch, I.M. Thompson, C.W. Ryan
Journal: Annals of Oncology (2023)
1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data
Authors: F. Bozorgmehr, F. Weykamp, T.R. Overbeck, N. Maguire, E.L. Buchmeier, M. Hammer-Hellmig, T.C. Gauler, M. Wermke, E.G.C. Troost, M. Ulmer, A-C. Mueller, K. Kokowski, B. Röper, T. Wehler, S. Hey-Koch, N-S. Consdorf, R. Behnisch, P. Christopoulos, M. Thomas, S. Rieken
Journal: Annals of Oncology (2023)
2032MO Correlation of safety and efficacy in atezolizumab therapy across indications
Authors: J. Naidoo, G. Durán-Pacheco, V. Maiya, M. Socinski, G.P. Sonpavde, J. Puente, L. Essioux, C.A. Carter, J.V. Cardona, R. Mohindra, S.G. Chandler
Journal: Annals of Oncology (2023)
1601P Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy
Authors: G. Guner, A. Erdemir, M.R. Onur, B.Y. Aktas, D.C. Guven, M. Kara, L. Özçakar, O. Dizdar
Journal: Annals of Oncology (2023)
2130P ATTITUDE - ATTrition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?
Authors: C.K. Chiodi, E. Martin, M.A. Franzoi, M. Pagliuca, D. Soldato, P. Lapidari, A. Barbier, J. Havas, J. Arvis, D. Boinon, G. Menvielle, L. Golli, R. Desjardin, G. Jacob, I.V. Vaz Luis, A. Di Meglio
Journal: Annals of Oncology (2023)
832P Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Authors: M. Gooyit, A. Payne, C. Carvalheda, D. Evans, C. Radoux, S. Richards, J. Besnard, S. Varzandeh, A. Gavard, S. Robinson, F. Breitgoff, A. Cooke, A. Bradley, M. Dominguez, P. Ray
Journal: Annals of Oncology (2023)
2207P Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Authors: H.M. O'Sullivan, A. John, N. Tokaca, C. Milner-Watts, J. Bhosle, A.R. Minchom, M. Davidson, M.E.R. O'Brien, A. George, S. Popat
Journal: Annals of Oncology (2023)
830P Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
Authors: J.M. Berger, A. Kienzle, T. Hatziioannou, E. Tomasich, M. Mayerhoefer, B. Kiesewetter-Wiederkehr, A.S. Berghoff, M. Preusser, M. Raderer
Journal: Annals of Oncology (2023)
1908P Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Authors: M. Smigelski, S. Sudhaman, S. Nagpal, B. Brooks, T. Gerald, R. Sanchez-Mendez, C. Battista, R. Bhanvadia, A. Kazarian, S. Choi, C. Carson, T. Mahmood, E.Z. White, A. ElNaggar, M.C. Liu, M. Metcalf, R.R. McKay, A. Corcoran, V. Margulis, W. Huang
Journal: Annals of Oncology (2023)
2158P A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Authors: K. Ouali, I. Deneche, L. Seknazi, R. Bahleda, A. Vozy, P. Vuagnat, F-X. Danlos, V. Goldschmidt, A. Bayle, P. Martin Romano, A. Hollebecque, J-M. Michot, A. Marabelle, S. Postel-Vinay, A. Gazzah, C. Smolenschi, Y. Loriot, S. Ponce Aix, S. Champiat, C. Baldini
Journal: Annals of Oncology (2023)
1279P Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
Authors: E. Amorin, H.A. Perroud, L.G-H. Hellal, S.V. Francisco, A.P. Guerrero, A. Vasquez, L.F.T. Gallegos, N. Donner, R. Huggenberger, L. Corrales
Journal: Annals of Oncology (2023)
1283P Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
Authors: D.J. Hughes, E. Josephides, R. O'Shea, T. Manickavasagar, C. Horst, S. Hunter, P. Taniere, D. Nonaka, J. Spicer, V. Goh, A. Bille, E.M. Karapanagiotou, G. Cook
Journal: Annals of Oncology (2023)
2154P Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Authors: M. Alameda-Guijarro, D. Sanchez Cabrero, A. Rueda-Lara, G. Martin-Montalvo Perez, R. Marcano, A. Garcia Leal, P. Zwisler Contreras, J.P. López, L. Ruiz Jimenez Ubeda
Journal: Annals of Oncology (2023)
2204P Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Authors: M. Guardamagna, B. Villaescusa Gonzalez, M.R. María Dolores, E. Zamorano Gonzalez, I. Ramos Garcia, A. Mesas Ruiz, J.M. Trigo Perez, A. Cantero, V. Gutierrez Calderon, J.M. Jurado García, A. Rueda Dominguez, R. Mongil, R. Arrabal, E. Alba Conejo, M. Cobo Dols, J.C. Benitez Montanez
Journal: Annals of Oncology (2023)
2143P Mortality within 30 days after last dose of intravenous systemic anti-cancer therapy: Single-center, one-year, retrospective analysis
Authors: O. Sutcuoglu, T.E. Çetin, A. Uner, N. Günel, G. Savaş, A. Özet, N. Ozdemir, O. Yazici
Journal: Annals of Oncology (2023)
2137P Impact of supportive care on the quality of life (QoL) of hospitalized cancer patients (pts)
Authors: J. Sanz Beltran, O. Mirallas, F. Bosma, M.A. Molina Pérez, C. Salva, K.S. Vega Cano, D.A. Gomez Puerto, D.E. López Valbuena, J.M. Ucha Hermida, G. Molina Lores, M. Roca Herrera, C. Sola Sahun, D. Romero Montenegro, S. Serradell, D. Paez, J. Carles Galceran, B. Martin Cullell
Journal: Annals of Oncology (2023)
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Authors: X. Liu, R. Zhong, J. Huang, Z. Chen, H. Xu, L. Lin, Q. Cai, M. He, S. Lao, H. Deng, C.C. Li, J. Li, R. Zeng, Y. Zheng, X. Liu, W. Liang, J. He
Journal: Annals of Oncology (2023)
1882O RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study
Authors: X. Sheng, M. Ye, Q. Zou, P. Chen, Z. He, B. Wu, D. He, C. He, X. Xue, Z. Ji, H. Chen, S. Zhang, Y. Liu, W. Zhai, X. Zhang, C. Fu, D. Xu, M. Qiu, Y. Huang, J. Guo
Journal: Annals of Oncology (2023)
2196P PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Authors: D.C.C. Christoph, M. Metzenmacher, S. Bölükbas, J. Volmerig, G. Nilius, D. Moka, H. Hautzel
Journal: Annals of Oncology (2023)
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Authors: W. Guo, L. Zhao, J. Zhao, S. Wang, X. Tao, L. Li, Y. Mao, F. Tan, Y. Gao, N. Wu, J. Ying, Q. Xue, N. Li, S. Gao, J. He
Journal: Annals of Oncology (2023)
1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
Authors: M.M. Awad, P.M. Forde, N. Girard, J.D. Spicer, C. Wang, S. Lu, T. Mitsudomi, E. Felip, S. Broderick, S.J. Swanson, J.R. Brahmer, K.M. Kerr, G. Saylors, K-N. Chen, J.L. Cai, J. Mahmood, J. Neely, D. Balli, N. Hu, M. Provencio Pulla
Journal: Annals of Oncology (2023)
Patient-physician concordance in age, sex, and race is not associated with increased trust, satisfaction, empathy, or physician’s perception of a difficult patient in Singapore
Authors: Ellie Choi, Kalyani Rajesh Patwardhan, Valencia Long, Yiong Huak Chan, Yik Weng Yew, Hazel H. Oon, Steven Thng, Chris Tan, Nisha Suyien Chandran, Phillip Phan
Journal: Journal of the American Academy of Dermatology (2023)
1183MO Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable prognosis by multiomics analysis: A multicenter retrospective cohort study (GARNET)
Authors: T. Shibuki, N. Mizuno, N. Kobayashi, H. Hirano, T. Tsuchikawa, S. Matsumoto, H. Okuyama, E. Sasaki, K. Shinjo, R. Yamaguchi, T. Kawata, W. Hosoda
Journal: Annals of Oncology (2023)
1969P Intratumoral immune infiltrates in chondrosarcoma (ChS)
Authors: P. Rutkowski, A. Szumera-Ciećkiewicz, A.E. Zając, J. Tuziak, M. Wągrodzki, P. Michalak, P. Teterycz, E. Palmerini, M. Gambarotti, G. Frega, M. Pierini, A. Righi, G. Magagnoli, A. Dutour, M. Jean-Denis, T. Ibrahim, J-Y. Blay, A.M. Czarnecka
Journal: Annals of Oncology (2023)
838P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Authors: O.O. Oluwole, M.D. Ray, J.M. Chen, K. Chan, I. Zhang, S. Keeping, H. Smith, C.L. Bellasis Spooner, A.R. Patel, F.L. Locke
Journal: Annals of Oncology (2023)
1899P Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Authors: G. Gebrael, Y. Jung Jo, V. Mathew Thomas, H. Li, G. Galarza Fortuna, K. Sahu, N. Sayegh, N. Tripathi, B. Chigarira, A. Srivastava, C. Hage Chehade, B. Nordblad, E. Dal, J. Brundage, B.L. Maughan, N. Agarwal, U. Swami
Journal: Annals of Oncology (2023)
1898P Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)
Authors: U. Swami, Y. Jung Jo, V. Mathew Thomas, G. Gebrael, H. Li, N. Sayegh, N. Tripathi, A. Srivastava, B. Nordblad, E. Dal, J. Brundage, P. Campbell, G. Galarza Fortuna, C. Hage Chehade, B.L. Maughan, N. Agarwal
Journal: Annals of Oncology (2023)
2191P Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Authors: S. Schmid, L. Holer, M. Frueh, K-L. Koster, S.I. Rothschild, C. Britschgi, L. Boos, L. Frehner, S. Cardoso Almeida, Y. Metaxas, M.T. Mark, P.R. Froesch, W-D. Janthur, A.T. Allemann, C. Waibel, C. Vonder Mühll-Schill, F.W.F. Cerciello, L.A. Mauti
Journal: Annals of Oncology (2023)
1295P Prospective trial of immuno-(chemo)therapy prior to resection, definitive chemo-radiotherapy, or palliative therapy in patients with borderline resectable or oligometastatic non-small cell lung cancer (KOMPASSneo)
Authors: M. Faehling, K. Lehrach, S. Fallscheer, B. Schwenk, S. Kramberg, J. Sträter, S. Eschmann, M. Hdetzel, R. Sätzler, F. Heinzelmann
Journal: Annals of Oncology (2023)
739P Penile squamous cell carcinoma tissue associated macrophages captured by multiplex immunfluorence are associated with clinical outcomes
Authors: J. Chahoud, F. Ionescu, M. Paravathaneni, L. Zemp, A. Yu, S. Eschrich, Y. Kim, D. Grass, J. Dhillon, B. Manley, P. Spiess
Journal: Annals of Oncology (2023)
1610P A new updated prognostic index for patients with brain metastases (BM) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology: METASNCore project
Authors: P. Flores Paco, M.L-H. López, I. Lopera, A. Vargas Aliaga, G.M. Guevara, L. Rodríguez Ruiz, J.A. Camús, J.L. González, E.D. Inga Saavedra, M. Montero Gómez, A. Palacios, J. De la Haba Rodriguez, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
2199P Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Authors: J. Derks, D. Leunissen, L. Moonen, J. von der Thüsen, M. den Bakker, L. Hillen, R. van Suylen, R. Damhuis, T. van den Bosch, L. Lap, A. Sexton Oates, L. Fernandez-Cuesta, A-M.C. Dingemans, E-J. Speel
Journal: Annals of Oncology (2023)
1188P Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Authors: A. Crymes, M.G. Evans, A. Elliott, J.R. Lozada, E. Carneiro, B.A. Carneiro, E. Lou, H.P. Soares, E.S. Antonarakis, C.J. Ryan, C. Nabhan, J. Marks, H. Beltran, J.H. Hwang
Journal: Annals of Oncology (2023)
2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Authors: S.M. Cedres Perez, A.A. Valdivia, J.D. Assaf Pastrana, P. Iranzo Gomez, A. Callejo Perez, N. Pardo Aranda, A.F. Navarro Mendivil, A. Martinez-Marti, I. Priano, J.M. Ucha Hermida, E. Garcia-Galea, J. Gonzalo, R. Caro, C. Carbonell, R. Amat, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2023)
1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Authors: A. Lemelin, K. Takemura, D.J. Boyne, M.T. Warkentin, D.R. Brenner, W.Y. Cheun, J.C. Wells, C. Labaki, B.A. McGregor, N.S. Basappa, L.A. Meza, S.K. Pal, B. Beuselinck, R.R. McKay, B.E. Szabados, T.B. Powles, T. Yuasa, L. Ludwig, T.K. Choueiri, D.Y.C. Heng
Journal: Annals of Oncology (2023)
2381P Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Authors: S. Schuck, P. Loussikian, A. Mebarki, J. Malaab, P. Foulquié, M. Talmatkadi, M. Kearney
Journal: Annals of Oncology (2023)
2390P Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Authors: K.H. Kwok, O. Laurin, S. Baculea, S. Côté, S. Spigelman, R. Szulkin, F. Schain, C.V. Jones, M. Aly
Journal: Annals of Oncology (2023)
2167P Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Authors: M.T. Mark, A. Rojas Mora, T. Winder, A. Stathis, A. Jakob, G. Müller, S. Hayoz, P. Reimann, U. Petrausch, R.A.F. von Moos
Journal: Annals of Oncology (2023)
842P Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Authors: Y-C. Wei, F. Qi, B-M. Zheng, C-G. Zhang, Y. Xie, C. Bo, W-X. Liu, W. Liu, H. Fang, S. Qi, D. Zhang, Y. Chai, Y. Li, W. Wang, Y. Song, J. Zhu, M. Dong
Journal: Annals of Oncology (2023)
2173P Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Authors: N. Cunningham, M.M. Fouda, V. Vengadasalam, R. Macwana, K. Day, J. Nobbs, A.J.S. Furness, L.M. Pickering, S. Turajlic, J. Larkin, N.M.L. Battisti, K. Young
Journal: Annals of Oncology (2023)
1907P Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Authors: L. Kinget, S. Naulaerts, J. Govaerts, I. Vanmeerbeek, J. Sprooten, R.S. Laureano, E. Roussel, A.T.L. Verbiest, D. Lambrechts, B. Boeckx, J. Zucman-Rossi, M. Albersen, M. Baldewijns, S. Tejpar, B. Beuselinck, A.D. Garg
Journal: Annals of Oncology (2023)
2159P Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Authors: M. Li, M.S. Furqan, S.L.A. Pang, J.L. Low, C. Choong, M. Ooi, Y.S. Ng, M.Z. Chen, F. Ho, J. Tey, Y. Yao, M. Chun, N. Barr Kumarakulasinghe
Journal: Annals of Oncology (2023)
2136P Prostate cancer supportive care (PCSC) program for patients and partners: A model for meeting an unmet need for PC patients
Authors: C.S. Higano, M. Sundar, C. Zarowski, M. Lui, N. Pratap, J. Egilson, A. Holmes, N. Ivanov, M. Dayan, A. Hudon-Kaide, P. Griggs, C. Maurice-Dror, R. Ho, D. Sare, A. Hwang, W. Eugenia, J. Bentley, R. Flannigan
Journal: Annals of Oncology (2023)
Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
Authors: Shamik Mascharak, Jason L. Guo, Deshka S. Foster, Anum Khan, Michael F. Davitt, Alan T. Nguyen, Austin R. Burcham, Malini S. Chinta, Nicholas J. Guardino, Michelle Griffin, David M. Lopez, Elisabeth Miller, Michael Januszyk, Shyam S. Raghavan, Teri A. Longacre, Daniel J. Delitto, Jeffrey A. Norton, Michael T. Longaker
Journal: Cell Reports Medicine (2023)

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death. Hallmarks include desmoplasia with variable extracellular matrix (ECM) architecture and a complex microenvironment with spatially defined tumor, stromal, and immune populations. Nevertheless, the role of desmoplastic spatial organization in patient/tumor variability remains underexplored, which we elucidate using two technologies. First, we quantify ECM patterning in 437 patients, revealing architectures associated with disease-free and overall survival. Second, we spatially profile the cellular milieu of 78 specimens using codetection by indexing, identifying an axis of pro-inflammatory cell interactions predictive of poorer outcomes. We discover that clinical characteristics, including neoadjuvant chemotherapy status, tumor stage, and ECM architecture, correlate with differential stromal-immune organization, including fibroblast subtypes with distinct niches. Lastly, we define unified signatures that predict survival with areas under the receiver operating characteristic curve (AUCs) of 0.872-0.903, differentiating survivorship by 655 days. Overall, our findings establish matrix ultrastructural and cellular organizations of fibrosis linked to poorer outcomes.
2400P Frequency and nature of genomic alterations (GA) in ERBB2-altered urothelial bladder cancer (UBC)
Authors: R. Talukder, J. Leary, T. Enright, D.R. Bakaloudi, G. Bratslavsky, J.M. Jacob, P. Spiess, R. Li, A. Necchi, A. Kamat, D.C. Pavlick, N.A. Danziger, R. Huang, D.I. Lin, J.S. Ross, P. Grivas
Journal: Annals of Oncology (2023)
1896P Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Authors: T.R. Geldart, L.M. Pickering, A. Sharma, D. Scott, O.A. Parikh, None S. coleman, P. Dhokia, M. Hale, L. Vaz
Journal: Annals of Oncology (2023)
845P A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Authors: M. Tang, Z. Antic, P. Fardzadeh, C. Schröder, S. Pietzsch, J. Lentes, W. Hofmann, L. von Wolffersdorff, M. Zimmermann, M. Horstmann, W. Nejdl, G. Cario, M. Stanulla, A.K. Bergmann
Journal: Annals of Oncology (2023)
2209P Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Authors: J.A. Duarte, D.N. Silva, J.L. Mendes, R.Q. Ferreira, M.A. Montenegro, R.S. Vicente, A. Duarte Mendes, R.R. Freitas, T.S. Martins, B.M. Silva, M. Machete, A.R. Fortuna, R. Correia das Neves, J. Correia, P. Simões, J. Moreira-Pinto, T. Timóteo, J.L.C. Passos-Coelho
Journal: Annals of Oncology (2023)
732P Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis
Authors: C. Seidel, U.F.F. De Giorgi, N. Engel, M. Hentrich, S. Zschäbitz, E. Conolly, A.J. Weickhardt, P. Grimison, V. Wong, C. Oing, W. Alsdorf, C. Schaefers, C. Bokemeyer, B. Tran
Journal: Annals of Oncology (2023)
1182O Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
Authors: L. de Mestier du Bourg, D. Cohen, J. Masliah-Planchon, S. Sivakumar, O. de rycke, O. Hentic Dhome, Z. Fleischmann, E.S. Sokol, B. Decker, A. Couvelard, P. Ruszniewski, I. Bieche, J. Cros
Journal: Annals of Oncology (2023)
1288P Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Authors: M.I. Dacoregio, C.E.D.R. Castro, I.F. Michelon, C. Stecca, M. Silveira Vilbert
Journal: Annals of Oncology (2023)
1965P Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Authors: J. Roszik, C. Alvarez-Breckenridge, K.C. Akdemir, J. Bird, S. Patel, A. Lazar, W-L. Wang, A. Ghia, D. Grosshans, A. Bishop, C. Tatsui, F. Demonte, L. Rhines, C. Yee, S. Patel, S. Raza, A.P. Conley
Journal: Annals of Oncology (2023)
2206P Detection of circulating KRAS4A and KRAS4B isoforms in patients with metastatic lung adenocarcinoma treated with pembrolizumab or chemotherapy plus pembrolizumab by liquid biopsy: Clinical impact and association with circulating PD-L1
Authors: S. Palladino, A. Ruzzo, R. Emili, V. Catalano, M. De Lisa, D. Sarti, M. Magnani, F. Graziano, R. Chiari
Journal: Annals of Oncology (2023)
1303P Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Authors: E.B. Ulas, A. Vrijmoet, S. Koomen, I. Houda, C. Dickhoff, I. Bahce, S. Senan, T.D. de Gruijl, M. Fransen, F. van Maldegem, T. Radonic, F. Schneiders
Journal: Annals of Oncology (2023)
1184MO Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)
Authors: M.E. Pavel, L. Fischer von Weikersthal, G. Klöppel, K. Krause, L. Apostolidis
Journal: Annals of Oncology (2023)